1. Home
  2. ACXP vs ADIL Comparison

ACXP vs ADIL Comparison

Compare ACXP & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.42

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$5.39

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACXP
ADIL
Founded
2017
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
7.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
ACXP
ADIL
Price
$1.42
$5.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$95.50
$37.50
AVG Volume (30 Days)
149.8K
65.1K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.13
52 Week High
$8.34
$5.17

Technical Indicators

Market Signals
Indicator
ACXP
ADIL
Relative Strength Index (RSI) 45.67 73.77
Support Level $1.36 $1.63
Resistance Level $1.79 N/A
Average True Range (ATR) 0.13 0.58
MACD 0.01 0.12
Stochastic Oscillator 21.69 96.21

Price Performance

Historical Comparison
ACXP
ADIL

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

Share on Social Networks: